Achema middle east

Sharp Clinical Supports Development of Novel COVID-19 Vaccines and Treatments

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Sanofi, Earendil Partner on Autoimmune Disease Treatments

Sanofi and Earendil Labs have announced a strategic collaboration...

Insilico and Servier Join Hands for New Oncology Therapies

Insilico Medicine has gone ahead with a multi-year research...

Specialized Laboratory Equipment Requirements for Biologics and Biosimilar Development

The development of complex biological molecules requires a specialized toolkit distinct from traditional small-molecule chemistry. This article details the critical laboratory equipment—from advanced bioreactors to high-resolution characterization tools—that enables the precise engineering and rigorous analysis required for successful biologics and biosimilar innovation.
- Advertisement -

Sharp Clinical, part of UDG Healthcare and a leading provider of global clinical supply services, has confirmed that it is involved in supporting six clinical trials related to COVID-19.

The company is currently delivering clinical trial packaging, labeling and distribution services for two biotech organizations that are developing potential vaccines for the virus.

Sharp is also delivering a combination of services to support multiple hydroxychloroquine projects, including placebo manufacturing, packaging, labeling, distribution and comparator sourcing, as clinical trials have launched globally to assess the drugs suitability to treat COVID-19 symptoms.

Frank Lis, President of Sharp Clinical said: “We are very proud of the work we do every day in support of our pharma clients, but never more so than today as we actively support our clients’ clinical studies related to COVID-19.

“In the face of this global pandemic, the clinical trials industry continues to focus its attention on the discovery and development of potential vaccines and treatments for COVID-19 and Sharp Clinical is playing its part.

“It is a privilege to be able to contribute to these trials and Sharp will continue to prioritize these COVID-19 projects. We are doing all we can to protect our own employees in their vital work, so that they can support the industry’s efforts in fighting the disease”.

Sharp’s Packaging division also packages and distributes many life-sustaining and life-saving medicines that are needed to maintain peoples’ health, including some that treat COVID-19 symptoms, such as high fever.

ABOUT SHARP
Sharp, part of UDG healthcare, is a global leader in contract packaging and clinical services. Operating from eight state-of-the-art facilities across the US and Europe, Sharp has built an international reputation for delivering cost-effective blister packaging, bottling, secondary assembly and labelling of injectable presentations, compliance packaging, formulation and manufacturing services, label design and printing. Sharp is also a world leader in ’Track and Trace’ and serialization services, with over 11 years’ experience in implementing serialized solutions for its pharma clients.

Sharp Clinical
Sharp Clinical offers a full complement of clinical trial services, including analytical, formulation development, clinical manufacturing and packaging, storage and distribution. Sharp also offers an interactive response technology (IRT) platform which can accommodate simple to complex randomization schemes as well as clinical supply chain management.

During 2018, Sharp Clinical invested $36 million in new dedicated facilities in both the US and the UK and can offer QP services for European distribution. We service every phase of the drug lifecycle from Phase 1 through to commercialization and through our global network of over 30 depots we can distribute to every region of the world. Our highly experienced team will help you optimize every aspect of your clinical trial.

Latest stories

Related stories

Sanofi, Earendil Partner on Autoimmune Disease Treatments

Sanofi and Earendil Labs have announced a strategic collaboration...

Insilico and Servier Join Hands for New Oncology Therapies

Insilico Medicine has gone ahead with a multi-year research...

Specialized Laboratory Equipment Requirements for Biologics and Biosimilar Development

The development of complex biological molecules requires a specialized toolkit distinct from traditional small-molecule chemistry. This article details the critical laboratory equipment—from advanced bioreactors to high-resolution characterization tools—that enables the precise engineering and rigorous analysis required for successful biologics and biosimilar innovation.

Next-Generation Laboratory Equipment Redefining Drug Discovery Workflows

Advanced technologies such as AI-integrated high-throughput screening platforms and automated assay systems are fundamentally transforming early-stage pharmaceutical research. These innovations address critical bottlenecks in productivity and data quality, enabling research teams to accelerate timeline-to-candidate selection while enhancing the predictive accuracy of drug discovery campaigns.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »